Asia Pacific Non Small Cell Lung Cancer Diagnostics Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2021 –2028 |
 Taille du marché (année de référence) |
USD 291.14 Million |
 Taille du marché (année de prévision) |
USD 865.62 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché du diagnostic du cancer du poumon non à petites cellules en Asie-Pacifique, par type de cancer (adénocarcinome pulmonaire (LUAD), carcinome épidermoïde pulmonaire (LUSC), carcinome à grandes cellules et autres), produit (réactifs et kits, instruments et services et logiciels), test (test d'imagerie, test moléculaire, biopsie, cytologie des expectorations, thoracentèse, immunohistochimie et autres), utilisateur final (hôpital, laboratoires cliniques, universitaires et autres), pays (Chine, Thaïlande, Australie, Japon, Corée du Sud, Singapour, Malaisie, Indonésie, Philippines, Inde et reste de l'Asie-Pacifique) Tendances et prévisions de l'industrie jusqu'en 2028.
Analyse et perspectives du marché : Marché du diagnostic du cancer du poumon non à petites cellules en Asie-Pacifique
Le marché du diagnostic du cancer du poumon non à petites cellules en Asie-Pacifique devrait atteindre 865,62 millions USD d'ici 2028, contre 291,14 millions USD en 2020, avec un TCAC constant de 14,6 % au cours de la période de prévision de 2021 à 2028.
Le cancer du poumon non à petites cellules est une maladie dans laquelle des cellules malignes ou des cellules cancéreuses se forment dans les tissus des poumons. Il en existe différents types, et chaque type contient des cellules cancéreuses différentes qui se développent et se propagent de manière particulière. Les types de cancer du poumon non à petites cellules (CPNPC) sont le carcinome épidermoïde, le carcinome à grandes cellules et l'adénocarcinome. Dans le cas du carcinome épidermoïde, le cancer se forme dans les cellules fines et plates qui tapissent l'intérieur des poumons et est appelé carcinome épidermoïde. Le carcinome à grandes cellules commence dans plusieurs types de grandes cellules. Le cancer de type adénocarcinome commence dans les cellules qui tapissent les alvéoles et produisent des substances telles que le mucus. L'un des risques importants du cancer du poumon non à petites cellules (CPNPC) est le tabagisme et les symptômes comprennent une toux qui ne disparaît pas et un essoufflement. Divers tests sont utilisés, tels que des tests d'imagerie, des tests moléculaires, des biopsies et autres, pour diagnostiquer et examiner le stade du cancer. Le diagnostic est essentiel pour identifier la maladie à temps afin qu’un traitement approprié puisse être administré aux patients.
Les facteurs qui stimulent la croissance du marché du diagnostic du cancer du poumon non à petites cellules sont l'utilisation de l'intelligence artificielle et de l'apprentissage automatique pour améliorer les procédures de diagnostic, couplée à l'augmentation d'un certain nombre de populations gériatriques plus sensibles au cancer du poumon non à petites cellules. Alors que la forte concurrence sur le marché et la chaîne d'approvisionnement perturbée en raison de la pandémie de COVID-19 peuvent remettre en cause la croissance du marché du diagnostic du cancer du poumon non à petites cellules.
En outre, l’augmentation des dépenses de santé dans les pays en développement et l’adoption croissante de nouvelles technologies pour diagnostiquer le cancer du poumon non à petites cellules créeront d’énormes opportunités pour le marché mondial du diagnostic du cancer du poumon non à petites cellules. D’autre part, la forte concurrence sur le marché et la chaîne d’approvisionnement perturbée en raison de la pandémie de COVID-19 devraient mettre à l’épreuve le marché mondial du diagnostic du cancer du poumon non à petites cellules.
The non-small cell lung cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the non-small cell lung cancer diagnostics market scenario, contact Data Bridge Market Research for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market Scope and Market Size
The Asia-Pacific non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of cancer type, the Asia-Pacific non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), large cell carcinoma, and others. In 2021, the lung adenocarcinoma (LUAD) segment is expected to dominate the non-small cell lung cancer diagnostics market due to the increasing number of adenocarcinoma lung cancer patients in the world.
- On the basis of products, the Asia-Pacific non-small cell lung cancer diagnostics market is segmented into reagents and kits, instruments and services, and software. In 2021, the instrument is expected to dominate the non-small cell lung cancer diagnostics market due to the increasing demand for high technological instruments to diagnose non-small cell lung cancer with accuracy.
- On the basis of the test, the Asia-Pacific non-small cell lung cancer diagnostics market is a segmented imaging test, molecular test, biopsy, sputum cytology, thoracentesis, immunohistochemistry, and others. In 2021, the molecular test segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing need for molecular tests for lung cancer diagnosis to provide proper treatment to patients.
- On the basis of end-user, the Asia-Pacific non-small cell lung cancer diagnostics market is segmented into hospitals, clinical laboratories, academics, and others. In 2021, the clinical laboratories segment is expected to dominate the non-small cell lung cancer diagnostics market due to the increase in research on non-small cell lung cancer in clinical laboratories.
Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market: Country Level Analysis
Asia-Pacific non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user.
Countries covered in the Asia-Pacific Non-small cell lung cancer diagnostics market report are China, Thailand, Australia, Japan, South Korea, Singapore, Malaysia, Indonesia, Philippines, India, and the Rest of Asia-Pacific.
The products segment in the China region is expected to grow with the highest share in the forecast period of 2021 to 2028 because of the increase in demand for diagnosis instruments to diagnose non-small cell lung cancer patients. The products segment in India is dominating the Asia-Pacific market owing to increased healthcare expenditure. The Philippines is leading the growth of the Asia-Pacific market for products segment is dominating in this country due to rising healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities By Major Market Players To Enhance The Awareness For Non-Small Cell Lung Cancer Diagnostics, Is Boosting The Market Growth Of Non-Small Cell Lung Cancer Diagnostics Market.
The non-small cell lung cancer diagnostics market also provides you with a detailed market analysis for every country's growth in a particular market. Additionally, it provides detailed information regarding the market players' strategy and their geographical presence. The data is available for the historical period 2010 to 2019.
Competitive Landscape and Asia-Pacific Non-small cell lung cancer diagnostics Market Share Analysis
Asia-Pacific Non-small cell lung cancer diagnostics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, India presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies' focus related to the non-small cell lung cancer diagnostics market.
Français Certains des principaux acteurs opérant sur le marché du diagnostic du cancer du poumon non à petites cellules sont Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, Biotheranostics, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, Dr. Lal PathLabs, RIVERAIN TECHNOLOGIES, PlexBio Co., Ltd, Oncimmune, Biodesix. parmi d'autres acteurs nationaux. Les analystes de DBMR comprennent les atouts de la concurrence et fournissent une analyse concurrentielle pour chaque concurrent séparément.
De nombreux contrats, accords et lancements sont également initiés par des entreprises du monde entier, ce qui accélère également le marché du diagnostic du cancer du poumon non à petites cellules.
Par exemple,
- En mars 2021, Agilent Technologies, Inc. a acquis Resolution Bioscience pour 550 millions USD afin de renforcer son activité dans les solutions oncologiques basées sur le séquençage de nouvelle génération (NGS)
- En mai 2021, QIAGEN a lancé le kit PCR therascreen KRAS RGQ approuvé par la FDA, qui aide à l'identification du cancer du poumon non à petites cellules (NSCLC) chez les patients
- En juin 2020, F. Hoffmann-La Roche Ltd a lancé un algorithme automatisé de pathologie numérique, l'analyse d'image uPath PD-L1 (SP263), pour diagnostiquer le cancer du poumon non à petites cellules (NSCLC) et améliorer la rapidité et la précision du traitement diagnostique.
La collaboration, le lancement de produits, l'expansion commerciale, les récompenses et la reconnaissance, les coentreprises et d'autres stratégies des acteurs du marché renforcent l'empreinte de l'entreprise sur le marché du diagnostic du cancer du poumon non à petites cellules, ce qui constitue également un avantage pour la croissance des bénéfices de l'organisation.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 CANCER TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
4.2 PRODUCT AND BRAND ANALYSIS: ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
4.3 ABBOTT LABORATORIES-
4.4 F. HOFFMANN-LA ROCHE LTD -
4.5 AGILENT TECHNOLOGIES, INC.
4.6 QIAGEN
4.7 THERMO FISHER SCIENTIFIC, INC
4.8 QUEST DIAGNOSTICS INCORPORATED
4.9 NEOGENOMICS LABORATORIES, INC.
4.1 NANOSTRING
4.11 JANSSEN PHARMACEUTICAL NV
4.12 INIVATA LTD
4.13 BIOMÉRIEUX SA
4.14 BIOTHERANOSTICS, INC.
4.15 ONCOCYTE CORPORATION
4.16 ECKERT & ZIEGLER
4.17 GENERAL ELECTRIC COMPANY
4.18 DR LAL PATHLABS
4.19 RIVERAIN TECHNOLOGIES
4.2 PLEXBIO CO.,LTD
4.21 BIODESIX
4.22 ONCIMMUNE
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN PREVALENCE OF LUNG CANCER ACROSS THE WORLD
5.1.2 GROWING NUMBER OF GERIATRIC POPULATION THAT IS MORE SUSCEPTIBLE TO NON-SMALL CELL LUNG CANCER
5.1.3 GROWING COLLABORATION PARTNERSHIP AND AGREEMENT BY THE KEY PLAYERS
5.1.4 GROWING USAGE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING TO IMPROVE THE DIAGNOSTIC PROCEDURES
5.1.5 INCREASING PREVALENCE OF UNHEALTHY LIFESTYLE THAT POSES A SERIOUS RISK OF LUNG CANCER
5.1.6 GROWING PRODUCT LAUNCHES
5.2 RESTRAINTS
5.2.1 CHALLENGES ASSOCIATED WITH BRAND EQUITY
5.2.2 MAINTAINING HIGH LEVEL OF EXPERTISE FOR DIAGNOSIS PURPOSE
5.3 OPPORTUNITIES
5.3.1 RISING HEALTHCARE EXPENDITURE IN DEVELOPING REGION
5.3.2 INCREASING ADOPTION OF NEW TECHNOLOGY TO DIAGNOSE NON-SMALL CELL LUNG CANCER
5.3.3 INCREASE IN THE NUMBER OF APPROVALS FOR NON-SMALL CELL LUNG CANCER PRODUCTS
5.4 CHALLENGES
5.4.1 HIGH COMPETITION AMONG MARKET PLAYERS
5.4.2 DISTURBED SUPPLY CHAIN DUE TO COVID-19
6 IMPACT OF COVID-19 ON THE ASIA-PACIFIC NON SMALL CELL LUNG CANCER DIAGNOSTIC MARKET
6.1 IMPACT ON DEMAND
6.2 IMPACT ON SUPPLY CHAIN
6.3 IMPACT ON PRICE
6.4 CONCLUSION
7 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE
7.1 OVERVIEW
7.2 LUNG ADENOCARCINOMA (LUAD)
7.3 LUNG SQUAMOUS CELL CARCINOMA (LUSC)
7.4 LARGE CELL CARCINOMA
7.5 OTHERS
8 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 INSTRUMENTS
8.3 REAGENTS AND KITS
8.3.1 LUNG CANCER ASSAY KIT
8.3.2 MUTATION KIT
8.3.3 EXTRACTION KIT
8.3.4 SAMPLE PREPARATION KIT
8.3.5 SOLID TUMOUR KIT
8.3.6 OTHERS
8.4 SERVICES AND SOFTWARES
9 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST
9.1 OVERVIEW
9.2 MOLECULAR TEST
9.2.1 RT-PCR
9.2.2 NEXT-GENERATION SEQUENCING (NGS)
9.2.3 DNA MICROARRAY
9.2.4 NEXT GENERATION CAPTURE
9.2.5 LAB-ON -A CHIP (LOAC)
9.2.6 MULTIPLEX CONVENTIONAL
9.2.7 PROTEIN MICROARRAY
9.2.8 OTHER
9.3 IMAGING TEST
9.3.1 PISITRON EMISSION TOMOGRAPHY (PET) SCAN
9.3.2 MAGNETIC RESONANCE IMAGING (MRI) SCAN
9.3.3 CT SCAN
9.3.4 BONE SCAN
9.3.5 OTHERS
9.4 IMMUNOHISTOCHEMISTRY
9.5 BIOPSY
9.6 SPUTUM CYTOLOGY
9.7 THORECENTESIS
9.8 OTHERS
10 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 CLINICAL LABORATORIES
10.3 HOSPITAL
10.4 ACADEMICS
10.5 INSTITUTES AND RESEARCH CENTERS
11 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 JAPAN
11.1.3 INDIA
11.1.4 SOUTH KOREA
11.1.5 AUSTRALIA
11.1.6 MALAYSIA
11.1.7 THAILAND
11.1.8 INDONESIA
11.1.9 SINGAPORE
11.1.10 PHILIPPINES
11.1.11 REST OF ASIA-PACIFIC
12 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 ABBOTT LABORATORIES
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 F. HOFFMANN-LA ROCHE LTD
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 QUEST DIAGNOSTICS INCORPORATED
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 GENERAL ELECTRIC COMPANY
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 NANOSTRING
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 AGILENT TECHNOLOGIES, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 BIODESIX
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BIOMERIEUX SA
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 BIOTHERANOSTICS
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 DR LAL PATHLABS
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 ECKERT & ZIEGLER
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 INIVATA LTD
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 JANSSEN PHARMACEUTICAL NV
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 NEOGENOMICS LABORATORIES, INC.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 ONCIMMUNE
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 ONCOCYTE CORPORATION
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
14.17 PLEXIBIO CO LTD
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 QIAGEN
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENTS
14.19 RIVERAIN TECHNOLOGIES
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 THERMO FISHER SCIENTIFIC INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
LIST OF TABLES
TABLE 1 AGING WORLD POPULATION
TABLE 2 U.K. X RAY DEMAND 2018
TABLE 3 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 4 ASIA-PACIFIC LUNG ADENOCARCINOMA (LUAD) IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC LUNG SQUAMOUS CELL CARCINOMA (LUSC) IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC LARGE CELL CARCINOMA IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC OTHERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC INSTRUMENTS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC SERVICES AND SOFTWARES IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC IMMUNOHISTOCHEMISTRY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC BIOPSY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2020
TABLE 20 ASIA-PACIFIC SPUTUM CYTOLOGY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC THORECENTESIS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC OTHERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC CLINICAL LABORATORIES IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC HOSPITAL IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC ACADEMICS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC INSTITUTES AND RESEARCH CENTERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 36 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 37 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 38 CHINA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 39 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 40 CHINA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 41 CHINA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 42 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 43 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 44 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 45 JAPAN REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 47 JAPAN IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 48 JAPAN MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 49 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 50 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 51 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 52 INDIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 53 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 54 INDIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 55 INDIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 56 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 58 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 59 SOUTH KOREA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 60 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 61 SOUTH KOREA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 62 SOUTH KOREA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 63 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 65 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 66 AUSTRALIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 67 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 68 AUSTRALIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 69 AUSTRALIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 70 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 71 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 72 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 73 MALAYSIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 74 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 75 MALAYSIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 76 MALAYSIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 77 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 79 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 80 THAILAND REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 81 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 82 THAILAND IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 83 THAILAND MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 84 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 86 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 87 INDONESIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 88 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 89 INDONESIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 90 INDONESIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 91 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 93 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 94 SINGAPORE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 95 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 96 SINGAPORE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 97 SINGAPORE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 98 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 100 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 101 PHILIPPINES REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 102 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 103 PHILIPPINES IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 104 PHILIPPINES MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 105 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 106 REST OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
Liste des figures
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 10 RISE IN THE GERIATRIC POPULATION THAT IS MORE SUSCEPTIBLE TO NON-SMALL CELL LUNG CANCER IS EXPECTED TO DRIVE THE ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
FIGURE 13 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2020
FIGURE 14 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020
FIGURE 15 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2020
FIGURE 16 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2020
FIGURE 17 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 18 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 19 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 20 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 21 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY LUNG CANCER TYPE (2021 & 2028)
FIGURE 22 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
